Because viruses don't wait for paperwork
Our pre-built and scalable vaccine offering enable faster trials, better site and patient experiences, and expedited data delivery.
Scale to fit your trial needs
Deploy quickly with pre-built Core
Deploy in as little as five weeks—while confidently meeting industry standards—with our pre-built set of tools intentionally configured for vaccine trial.
Our Core tools include:
- eScreening
- eConsent
- TeleVisit and Scheduling capabilities
- eCOA
- Customized notifications and reporting
Scale efficiently with Flex
It’s Core—with more. In addition to Core tools, Flex offers you a custom set of digital products tailored by our subject matter experts to meet your protocol’s needs.
With Flex, you also benefit from:
- Sensors and wearables
- More complex COAs
- Advanced system integrations
- Additional language support
- Access to partner capabilities
“This solution eliminates much of the technical build burden and can reduce trial launch timelines from more than 12 weeks on average”
VP Therapeutic Area Solutions - Customer Value Team
Vaccine specific experience, partnered with vaccine experts
Indications
Languages Enabled
Platform Participants
Frequently asked questions
With our “Core” vaccine offering you can deploy your trial in as little as 5 weeks from PDS to go-live.
Yes! Our platform provides real-time access to key safety data throughout your trial.
Yes. The need for rapid enrollment, changes in affected area, and need to remotely collect data are perfect for our pre-built solutions.
If it is a vaccine study, our offering is able to service your unique vaccine trial’s needs. Our SMEs can review protocol requirements and confirm it’s a good fit for our digital trial solutions.
The Vaccine offering is a pre-built, standardized solution that can be rapidly deployed and scaled across your portfolio.
The latest in vaccines
Medable enables over 90% eCOA adherence in vaccine trial
A leading biotech company came to Medable looking to conduct a vaccine trial. They were concerned that their trial’s participant population of persons aged 50+ years may be hesitant to use the sponsors’ chosen eCOAtrial technology, would not be engaged in the study, and therefore may not provide consistent trial data.
Learn how we drove success for them, including 90% eCOA adherence.
Bridging the gap: Ensuring sites are successful with Medable
For years, clinical research sites have been vocal about the technological challenges they face conducting trials. Obstacles such as multiple disparate systems per trial, an abundance of passwords, lack of interoperability, and other issues all showcase how technology can be as significant a hindrance as it is a boon. As a recent Forbes article suggests, if clinical research technology doesn’t empower sites, it risks slowing down the entire trial.
How we standardized deploying vaccine studies in five weeks
By Musaddiq Khan, VP, DCT Solutions
At Medable, we’re always looking to understand the changing environment of clinical research, and how we can help customers overcome the various challenges, risks, and scenarios that these changes bring.
For the past year, I, various clinicians, and research experts at Medable have been working closely to improve how we conduct research for various therapeutic areas. Much like the results shown in Tufts CSDD’s latest whitepaper, we believe that a well-thought, decentralized approach can help bring new therapies in historically challenging therapeutic areas to markets faster.
The result of this work is a brand-new decentralized approach we’re bringing to the market.